Design and Optimization of Trastuzumab-Functionalized Nanolipid Carriers for Targeted Capecitabine Delivery: Anti-Cancer Effectiveness Evaluation in MCF-7 and SKBR3 Cells
In view of the desired physicochemical properties, controlled drug release, and in vitro anticancer effectiveness, further in vivo investigations should be prioritized to validate its clinical application in HER2-positive breast cancer treatment. Nonetheless, the use of HER2-low MCF-7 cells in early assays highlights the importance of complementary validation in HER2-overexpressing models, as addressed by SKBR3 testing in this study.
Authors
- Yahya Alhamhoom (ORCID: https://orcid.org/0000-0002-8368-9047)
- Gurudutta Pattnaik (ORCID: https://orcid.org/0000-0002-3532-721X)
- Ismail Pasha (ORCID: https://orcid.org/0009-0005-2579-4032)
- Mohammed Muqtader Ahmed (ORCID: https://orcid.org/0000-0001-6911-0652)
- Bhabani Sankar Satapathy (ORCID: https://orcid.org/0000-0002-9175-8356)
- Shubhashree Das (ORCID: https://orcid.org/0000-0002-7747-3514)
- Mohamed Rahamathulla (ORCID: https://orcid.org/0000-0001-8826-3718)
- Sovan Pattanaik
Institutions
- Prince Sattam Bin Abdulaziz University (SA)
- Siksha O Anusandhan University (IN)
- Centurion University of Technology and Management (IN)
- King Khalid University (SA)
- University of Asmara (ER)
- GITAM University (IN)
Publication Details
- Journal
- International Journal of Nanomedicine
- Published
- 2025-10-01
- DOI
- https://doi.org/10.2147/ijn.s541332
- Citations
- 3
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 3.14